This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 4.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 124.39% and 14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 25% and 11.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging InMode (INMD) This Year?
by Zacks Equity Research
Here is how InMode (INMD) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
KalVista (KALV) Surges 15% on Update From Angioedema Study
by Zacks Equity Research
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
by Zacks Equity Research
Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
by Zacks Equity Research
Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
by Zacks Equity Research
Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
by Zacks Equity Research
New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
by Zacks Equity Research
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 6.67% and 14.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
by Zacks Equity Research
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.